On the homepage there is only one product for only one...

On the homepage there is only one product for only one indication, ATH434 ( an iron chelator) for MSA.

The plan for ATH434 is that it will be also used in PD. Now we are waiting for phase 2 results of MSA study and the results of the primate animal model of PD to start a clinical study in a small population. But ATH has over 100 patented other iron chelators. Animal studies have been done with these and at least one of these has demonstrated efficacy in dementia. There are many different potential indications for iron chelators in different ferroptosis diseases. The vast emerging literature on ferroptosis has shown that numerous diseases, such as cancers, neurodegeneration, and autoimmune diseases, are associated with ferroptosis, as are strokes and brain injuries. Meanwhile, recent studies have confirmed the relationship between ferroptosis and eye diseases including keratopathy, cataract, glaucoma, retinal ischemia-reperfusion injury, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and retinoblastoma, indicating the critical role of ferroptosis in ocular diseases. So there are very many potential indications for iron chelators. I think that Dr. Finkelstein has done a lot of work for these eye problems.

Now with this Masters news, there is again on the pipeline PBT2 and some over 100 Acyl hydrazones molecules targeting AD and brain amyloid.

We investors know that PBT2 reverses antibiotic resistance of over 30 antibiotics, and commercialization for that purpose is on the way.

So, IMO, there is quite a lot on the pipeline, in spite it is not told on the home page. The deal with Masters is a good step forward and with PBT2 commercialization against antibiotic resistance there will be ( perhaps soon) a gigantic step for ATH.